QIAGEN partners with Taiwan in nationwide TB screening effort
QuantiFERON®-TB Gold wins tender for testing subpopulations at risk for tuberculosis
Hilden, Germany, March 15, 2016 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that QuantiFERON®-TB Gold, the modern standard for accuracy in diagnosing latent tuberculosis (TB) infection, was selected by the Taiwan Centers for Disease Control (Taiwan CDC) to replace the tuberculin skin test for screening at-risk individuals five years and older.
Starting this month, Taiwan’s nationwide TB control effort will use QuantiFERON-TB Gold to test close contacts of patients with active tuberculosis, a contagious and life-threatening disease. In addition to treating patients with active TB, Taiwan will provide antibiotic treatment for patients identified as having latent TB infection (which if untreated can remain dormant and be activated years later). Only children younger than five years of age will be screened with the skin test.
“We are pleased to partner with Taiwan in combatting TB in their screening programs which will now employ the world’s most accurate test for latent TB infection, QuantiFERON-TB Gold. In addition to providing tests, QIAGEN will offer 25 training courses for public health nurses and medical technicians in all 22 counties,” said Dr. Masae Kawamura, Senior Director of Medical and Scientific Affairs for QIAGEN. “Around the world, QuantiFERON-TB technology has proven its value as an efficient, cost-effective testing solution to aid in TB control efforts. Screening at-risk populations for latent TB infection allows early treatment and prevention of the active disease, which is contagious and requires aggressive treatment with antibiotics.”
The Taiwan CDC joins authorities from many other countries in adopting the modern QuantiFERON-TB Gold test, based on interferon-gamma release assay (IGRA) technology, for screening at-risk subpopulations such as contacts of active TB patients, healthcare workers, HIV patients and immune-compromised persons as part of a “screen and treat” strategy for latent TB infection. Taiwan reported 10,555 new cases of active TB in 2015, and the Taiwan CDC estimates it will need about 48,000 IGRA tests in 2016. QuantiFERON-TB Gold was the only IGRA test that has been selected by the Taiwan CDC in the tender.
QIAGEN partners with governments and health organizations around the world to fight tuberculosis – and continues to develop innovative new technologies. QuantiFERON-TB Gold is the modern standard for accuracy in latent TB infection diagnosis – faster, less labor-intensive and more accurate than the tuberculin skin test. The test’s clinical reliability and simpler administration enhance the accuracy of screening and improve the cost-effectiveness of TB control. In 2015 QIAGEN launched QuantiFERON-TB Gold Plus in Europe and other markets as a fourth-generation test with CE-IVD marking. To date, more than 20 million tests using QuantiFERON-TB technology have been distributed globally.
To learn more about QFT and QFT-Plus, please visit http://www.QuantiFERON.com.
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of December 31, 2015, QIAGEN employed approximately 4,600 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.
Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results, including without limitation its expected operating results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products in applied testing, personalized healthcare, clinical research, proteomics, women's health/HPV testing and nucleic acid-based molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products, the consummation of acquisitions, and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).